{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T19:28:24Z","timestamp":1769542104978,"version":"3.49.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Clin. Diabetes Healthc."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this research is to evaluate the clinical and economic benefits of semaglutide in patients with type 2 diabetes mellitus (T2DM) in real-world setting in tertiary hospital in Saudi Arabia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this single-center retrospective chart review study, patients were included if they were adults and diagnosed with T2DM for at least one year between January 2017 and December 2023. Patients were excluded if they had previously received glucagon-like peptide-1 receptor agonist (GLP-1RA). The primary outcomes were HbA1c level and Body Mass Index (BMI). Secondary outcomes were the number of outpatient visits, emergency room visits, hospitalization days and total per patient costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study included a total of 186 patients who were initiated on semaglutide. After 12 months on semaglutide, patients\u2019 median HbA1c was reduced from 8.9% [8.4 - 9.9] to 7.8% [7.2 - 8.4] (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.0001) and BMI from 34.8 kg\/m\u00b2 [31.2 - 38.5] to 32.6 kg\/m\u00b2 [29.5 - 37.1] (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.0001). The number of visits decreased from 3.8 \u00b1 1.6 to 2.9 \u00b1 1.5 visits. Hospitalization days reduced from 7.6 \u00b1 7.2 to 4.6 \u00b1 2.3 days. However, the total cost of care increased from SAR 8,660.6 [6,412.6 - 11,352.3] to 10,434.1 [8,738.4 - 12,553.4]. The total mean additional cost per patient per year was SAR 1,964. Subgroup analyses suggest greater efficacy and higher cost in patients with higher baseline HbA1c and BMI levels.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Semaglutide was associated with significant improvement in glycemic and weight-loss control in adults with T2DM, but this significant change was associated with higher overall cost mainly driven by medication cost.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcdhc.2025.1677695","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T06:41:55Z","timestamp":1769496115000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world clinical and budget impact of semaglutide in type 2 diabetes mellitus in tertiary hospital in Saudi Arabia"],"prefix":"10.3389","volume":"6","author":[{"given":"Hana A.","family":"Al-Abdulkarim","sequence":"first","affiliation":[{"name":"Ministry of National Guard Health Affairs, King Abdullah International Medical Research Center (KAIMRC)","place":["Riyadh, Saudi Arabia"]},{"name":"Doctoral School of Applied Informatics and Applied Mathematics, \u00d3buda University","place":["Budapest, Hungary"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nawaf Salih","family":"Alqahtani","sequence":"additional","affiliation":[{"name":"Ministry of National Guard Health Affairs, King Abdullah International Medical Research Center (KAIMRC)","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Al-Shraim","sequence":"additional","affiliation":[{"name":"Ministry of National Guard Health Affairs, King Abdullah International Medical Research Center (KAIMRC)","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar A.","family":"Almohammed","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Saud University","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176275","article-title":"Pathophysiology of type 2 diabetes mellitus","volume":"21","author":"Galicia-Garc\u00eda","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2017.15","article-title":"Global aetiology and epidemiology oftype 2 diabetes mellitus and its complications","volume":"14","author":"Zheng","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4137\/bmi.s38440","article-title":"Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients","author":"Sherwani","year":"2016","journal-title":"BiomarkerInsights"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2174\/1573399811666150724095130","article-title":"Diabetes Mellitus in SAUDI ARABIA: A Review of the RecentLiterature","author":"Dawish","year":"2016","journal-title":"Current Diabetes Reviews"},{"key":"B5","unstructured":"International Diabetes Federation\n          \n          2023"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4103\/sjmms.sjmms_394_22","article-title":"Prevalence of type 2 diabetes mellitus in the generalpopulation of Saudi Arabia, 2000\u20132020: A systematic review and meta-analysis of observationalstudies","volume":"11","author":"Jarrar","year":"2023","journal-title":"Saudi J Med Med Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13448","article-title":"Prevalence, risk factors, and interventions for obesity in Saudi Arabia: A systematic review","volume":"23","author":"Salem","year":"2022","journal-title":"Obes Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2022.155217","article-title":"A 2022 update on the epidemiology of obesity and a call to action: As its twin covid-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on","volume":"133","author":"Boutari","year":"2022","journal-title":"Metabolism"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00989-6","article-title":"Evaluatingthe Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting","volume":"12","author":"Capehorn","year":"2021","journal-title":"Diabetes Ther"},{"key":"B10","article-title":"Glucagon-Like peptide-1 receptor agonists","volume-title":"StatPearls -NCBI Bookshelf","author":"Collins","year":"2023"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2020.07.008","article-title":"Semaglutide Effects on Cardiovascular Outcomes inPeople With Overweight or Obesity (SELECT) rationale and design","volume":"229","author":"Ryan","year":"2020","journal-title":"Am Heart J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1515\/reveh-2015\u20130008revised","article-title":"Obesity and public health in the\/Kingdom of Saudi Arabia","volume":"30","author":"Aburizaiza","year":"2015","journal-title":"Rev Environ Health"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and Safety of Once-Weekly Food and Drug Administration. Ozempic (semaglutide) injection prescribing information, Semaglutide Monotherapy Versus Placebo in Patients With Type 2 Diabetes (SUSTAIN 1): A Double-Blind, Randomised, Placebo- Controlled, Parallel-Group, Multinational, Multicentre Phase 3a Trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.15605\/jafes.037.02.14","article-title":"Efficacy and safety of semaglutide for weight loss in obesity without diabetes: A systematic review and meta-analysis","volume":"37","author":"Tan","year":"2022","journal-title":"J ASEAN Fed Endocr Soc"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.5144\/0256-4947.2024.361","article-title":"Efficacy and safety of semaglutide: real-world tertiary care experience from Saudi Arabia","volume":"44","author":"Butt","year":"2024","journal-title":"\u201d Ann Saudi Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-023-01516-z","article-title":"Evaluating the clinical effectiveness and safety of semaglutide in individuals with uncontrolled type 2 diabetes. Real-world evidence from Saudi Arabia: the observational, multicenter, 15-month EVOLUTION study","volume":"15","author":"Alsheikh","year":"2024","journal-title":"Diabetes Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.7759\/cureus.82123","article-title":"Effects of semaglutide on glycemic control and body weight in patients with type 2 diabetes: A retrospective cohort study in a primary care setting","volume":"17","author":"Alzahrani","year":"2025","journal-title":"Cureus"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.09.909","article-title":"Once-weekly Semaglutide compared to other two GLP1-RAS available in the public healthcare system in the kingdom of Saudi Arabia: a relative cost of control analysis","volume":"22","author":"Alabdulkarim","year":"2019","journal-title":"ISPOR Eur"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2024.102057","article-title":"Cost consequence analysis of adding semaglutide to treatment regimen for patients with Type II diabetes in Saudi Arabia","volume":"32","author":"AlRuthia","year":"2024","journal-title":"Saudi Pharm J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2277056","article-title":"Budget impact of introducing oral semaglutide to the public healthcare benefit package in Saudi Arabia","volume":"26","author":"Alluhidan","year":"2023","journal-title":"J Med Econ"},{"key":"B21","unstructured":"Microsoft excel\n          \n          2024"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"B23","unstructured":"Tucker\n              ME\n            \n          \n          Medscape\n          Semaglutide 2.4 mg reduces all-cause hospital admissions\n          \n          2024"}],"container-title":["Frontiers in Clinical Diabetes and Healthcare"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcdhc.2025.1677695\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T06:41:57Z","timestamp":1769496117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcdhc.2025.1677695\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":23,"alternative-id":["10.3389\/fcdhc.2025.1677695"],"URL":"https:\/\/doi.org\/10.3389\/fcdhc.2025.1677695","relation":{},"ISSN":["2673-6616"],"issn-type":[{"value":"2673-6616","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"article-number":"1677695"}}